The company has a portfolio of five marketed products and over 25 programs in development, with a focus on oncology, rare diseases, gene and cell therapy, and other areas of high unmet need. Its subsidiaries operate in biotechnology, pharmaceutical, oncology, and therapeutics sectors. Fortress advances its pipeline through partnerships with leading academic research institutions and biopharmaceutical companies, and its streamlined operating structure fosters efficient drug development.